Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher

Oct 08, 06:33 PM
Headliner
Share
Subscribe

Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.

Share
Subscribe
Next
Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Key Findings of the NIAGARA and HIMALAYA Trials
by Pharmaceutical Executive